Kitazato (368A) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The key point this fiscal period is that, despite maintaining a high level of profitability, profit growth somewhat lagged revenue growth. Revenue was ¥7.93B (+9.3% YoY), Operating Income was ¥4.25B (+7.0%), Ordinary Income was ¥4.26B (+6.7%), and Net Income attributable to owners of the parent was ¥2.82B (+7.5%), resulting in both higher revenue and higher earnings. The Operating Income margin was extremely high at 53.5%; however, expenses increased relatively more than revenue, resulting in a slight decline in the margin compared with the same period of the previous year.

Factors Affecting Performance

【Revenue】Revenue was ¥7.93B, representing a 9.3% YoY increase. The company operates as a single segment, the Medical Equipment Business, and expanding demand drove the increase in revenue.

【Profit and Loss】Operating Income was ¥4.25B (+7.0% YoY), Ordinary Income was ¥4.26B (+6.7%), and Net Income was ¥2.82B (+7.5%). Although all increased, their growth rates remained below the 9.3% revenue growth rate. The cost of sales ratio was 33.7% and the SG&A expense ratio was 12.8%. As the relative cost burden increased during the revenue expansion phase, the Operating Income margin, while remaining high at 53.5%, declined compared with the same period of the previous year. Non-operating income and expenses, including a foreign exchange gain of ¥0.05B, supported Ordinary Income, but the impact was limited. Extraordinary income and expenses were virtually nonexistent, and the difference between Ordinary Income and Net Income was primarily attributable to income taxes and other taxes (effective tax rate: 33.9%). In conclusion, the company is in a phase of higher revenue and earnings accompanied by a slight decline in margins.

Segment Analysis

The Group operates as a single segment, the Medical Equipment Business, and does not disclose segment-level profit and loss information.

Key Financial Metrics

【Profitability】The Operating Income margin was 53.5% and the Net Income margin was 35.5%, both extremely high levels reflecting the high-value-added business structure, as indicated by the gross margin of 66.3%. However, the Operating Income margin declined slightly compared with the same period of the previous year, indicating reduced capacity to absorb costs accompanying revenue growth.【Cash Quality】Inventory days were 217 days on an annualized basis, while the cash conversion cycle was 237 days. Both indicate an extended working capital cycle, with inventory accumulation delaying cash collection.【Investment Efficiency】ROE was 14.5%, primarily due to the high Net Income margin, with virtually no contribution from financial leverage. Total asset turnover remained at 0.388x, as substantial cash and land assets constrained the turnover ratio.【Financial Soundness】The Equity Ratio was 95.1%, with liabilities accounting for only 4.9% of total assets. The company possesses extremely high financial safety, as demonstrated by a current ratio of 1,658.9%.

Cash Flow Analysis

Although the cash flow statement is not directly disclosed, cash flow trends can be inferred from changes in the balance sheet. Cash and deposits increased to ¥12.03B (including an assumed slight increase from the previous year's level of approximately ¥11.75B and the previous year's ¥11.46B based on ¥11,460 million). Meanwhile, inventory increased from the ¥0.39B range to ¥0.45B, with raw materials of ¥1.04B and work in process of ¥0.62B accumulating. The extended working capital cycle, reflected in inventory days of 217 days and a CCC of 237 days, is a drag on capital efficiency. The ample cash balance, equivalent to 58.9% of total assets, provides resilience against this working capital burden, and the risk of financial liquidity constraints is limited.

Quality of Earnings

The majority of earnings consists of recurring income from the core business, and extraordinary income and expenses have been virtually absent, resulting in limited distortion from temporary factors. Non-operating income includes a foreign exchange gain of ¥0.05B, which contributed to higher Ordinary Income, but its scale was limited to approximately 1.1% of Ordinary Income. The difference between Operating Income and Ordinary Income was only ¥0.01B, indicating a minimal impact from net financial income and expenses. Meanwhile, the effective tax rate was somewhat high at 33.9%, restraining the conversion of pretax income into Net Income. Inventory accumulation accompanied by an increase in inventories warrants attention to the quality of working capital from an accruals perspective, and a somewhat cautious assessment is warranted regarding the speed of earnings conversion into cash.

Earnings Forecast and Guidance

The full-year company forecasts are Revenue of ¥10.60B (+2.9% YoY), Operating Income of ¥5.37B (-7.1%), and Ordinary Income of ¥5.27B (-8.7%), indicating a plan that anticipates slowing revenue growth and lower earnings in the second half. The Q3 cumulative progress rates were 74.8% for Revenue, 79.0% for Operating Income, 80.8% for Ordinary Income, and 80.5% for Net Income, with earnings progress exceeding the standard 75% level. The combination of this progress and the full-year earnings decline plan suggests that increased costs or changes in the product mix may be incorporated into Q4.

Shareholder Returns

The Q2 dividend was ¥0 per share, while the full-year dividend forecast is ¥41.0, reflecting a structure concentrated in the year-end dividend. The forecast Payout Ratio against forecast full-year EPS of ¥87.46 is 46.9%. Calculated based on total dividends of approximately ¥1.64B against forecast full-year Net Income of ¥3.498B, the ratio is also at the same level. The strong financial base, including an Equity Ratio of 95.1% and cash and deposits of ¥12.03B, supports the feasibility of this dividend plan.

Risk Factors

1. Inventory accumulation and working capital efficiency: Inventory days (annualized) were 217 days and the CCC (annualized) was 237 days, both extended levels. If demand fluctuates or products become obsolete, this could result in valuation losses and deteriorating capital efficiency.

2. Business concentration risk: The company operates as a single-segment Medical Equipment Business, creating a structure in which regulatory changes, healthcare reimbursement systems, quality issues, and other factors could directly affect performance.

3. Achievability of the full-year earnings decline plan: The company forecasts a 7.1% YoY decline in Operating Income. Given the consistency of this forecast with the Q3 progress rate of 79.0%, increased costs or changes in the product mix are anticipated in Q4.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability significantly exceeds the industry median and is at an extremely high level even within the manufacturing industry.

Growth and Capital Efficiency

The growth rate also exceeds the industry median, with revenue expanding at a relatively rapid pace within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. The company continues to maintain highly profitable operations, with an Operating Income margin of 53.5%, a Net Income margin of 35.5%, and ROE of 14.5%, all significantly above the industry average.

2. While financial safety is extremely high, as indicated by an Equity Ratio of 95.1% and a current ratio of 1,658.9%, the extended working capital cycle, reflected in inventory days of 217 days and a CCC of 237 days, is observed as a structural issue.

3. Although the Q3 cumulative earnings progress rate exceeds the standard level of 75%, the full-year plan anticipates a decline in Operating Income, making the earnings trend in Q4 a key focus going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥607–¥642 at ±1% for the cost of equity, and ¥621–¥629 at ±0.1 for ω.

Notes:

• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit five-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was strong in absolute terms, although profit growth trailed revenue growth as gross-margin pressure modestly reduced operating leverage. Revenue increased 9.3% YoY to ¥7.934bn, while operating income rose 7.0% to ¥4.248bn. Net income increased 7.5% to ¥2.817bn and EPS was ¥70.43. The gross margin declined by 104bp YoY to 66.3%, as cost of sales grew 12.8%, faster than revenue. SG&A increased 10.3% to ¥1.016bn, marginally faster than sales, lifting the SG&A-to-sales ratio by 12bp to 12.8%. Consequently, the operating margin declined by 116bp to 53.5%, but remains exceptionally high for a manufacturing business. The net margin declined by 60bp to 35.5%, reflecting the lower operating margin. Ordinary income of ¥4.258bn was virtually equal to operating income, confirming that earnings remained principally operating-profit driven. Foreign-exchange gains were ¥48m, equivalent to only 0.6% of revenue and not material to the earnings outcome. There were no extraordinary items in the current period, supporting the recurring nature of reported profit. The 33.9% effective tax rate was broadly stable and reduced the tax burden factor to 0.661. Annualized ROE was 19.3%, supported by the 35.5% net margin and modest financial leverage of 1.05x. The balance sheet is exceptionally conservative, with cash and deposits of ¥12.027bn, a 1,658.9% current ratio, and D/E of 0.05x. Inventory efficiency is the principal operational concern: annualized DIO is 217 days and the annualized cash conversion cycle is 237 days. Detailed manufacturing inventory balances increased across raw materials, work in process, and finished goods, indicating greater capital commitment to production and stockholding. Q3 progress against full-year guidance is ahead of the normal 75% seasonal benchmark for revenue, operating income, and net income. However, the full-year plan implies a substantial Q4 operating-margin decline to approximately 42.2%, making execution, mix, and cost control in the final quarter important variables.

Profitability Analysis

Annualized ROE of 19.3% decomposes into a 35.5% net profit margin, 0.518x asset turnover, and 1.05x financial leverage. The dominant driver of returns is therefore exceptional profitability rather than balance-sheet leverage, which is appropriate given the company’s 95.1% equity ratio. The operating margin of 53.5% and gross margin of 66.3% place the medical-device business well above standard manufacturing profitability benchmarks. Margin direction weakened modestly, however: gross margin fell 104bp, operating margin fell 116bp, and net margin fell 60bp YoY. Cost of sales grew 12.8% YoY, exceeding 9.3% sales growth, and was the primary source of gross-margin compression. SG&A rose 10.3% YoY versus 9.3% revenue growth, creating a small additional operating-leverage headwind. Nevertheless, SG&A remained only 12.8% of sales, indicating substantial fixed-cost absorption and strong underlying economics. The five-factor DuPont profile shows an interest burden of 1.003, reflecting immaterial net financing effects, while the tax burden was 0.661. Interest expense was only ¥1m and interest coverage was 4,248x, so financing costs do not constrain profitability. Current-period earnings contain no extraordinary gains or losses; operating income therefore remains the clearest indicator of recurring earnings capacity. The sustainability question is not the current margin level but whether the forecasted Q4 margin compression reflects product mix, pricing, production costs, or deliberate investment.

Growth Assessment

The company delivered revenue growth of 9.3% YoY, with operating income growth of 7.0% and net income growth of 7.5%, demonstrating continued expansion but modest margin dilution. Growth was achieved within a single medical-device segment, making consolidated growth directly reflective of the core business rather than portfolio effects. Revenue progress is 74.8% of the ¥10.602bn full-year forecast, essentially in line with the 75% Q3 seasonal benchmark. Operating income progress is 79.0% of the ¥5.374bn plan, 4.0 percentage points ahead of the standard progress rate. Net income progress is 80.5% of the ¥3.498bn plan, 5.5 percentage points ahead of the benchmark. These progress rates provide a reasonable cushion against the full-year plan, without exceeding the 10 percentage-point threshold that would ordinarily signal a material guidance deviation. The forecast requires Q4 revenue of ¥2.668bn, operating income of ¥1.126bn, and net income of ¥681m. Implied Q4 operating margin is approximately 42.2%, materially below the 53.5% Q3 cumulative margin and the 50.7% full-year forecast margin. Management’s full-year plan calls for 2.9% revenue growth but a 7.1% decline in operating income, which indicates anticipated margin normalization despite continued top-line expansion. Manufacturing inventories also expanded in raw materials to ¥1.040bn, work in process to ¥618m, and finished goods to ¥453m; this may support deliveries but elevates the importance of demand conversion and production planning. The core growth test is whether inventory build and final-quarter sales convert without further gross-margin pressure.

Financial Health

Financial health is exceptionally strong. Current assets of ¥15.527bn exceed current liabilities of ¥936m by ¥14.591bn, producing a current ratio of 1,658.9% and a quick ratio of 1,610.5%. Cash and deposits of ¥12.027bn account for 58.9% of total assets and cover total liabilities of ¥1.006bn by approximately 12.0x. Total liabilities represent only 4.9% of total assets, while owners’ equity represents 95.1%, leaving the company with very low balance-sheet risk. D/E is 0.05x, materially below the 2.0x warning threshold. Current liabilities of ¥936m are readily covered by cash alone, so there is no short-term debt or maturity-mismatch concern evident from the reported balance sheet. Interest coverage of 4,248x further confirms that debt servicing is immaterial. Total equity increased ¥1.177bn YoY, or 6.4%, principally reflecting retained earnings growth. Cash increased ¥567m YoY to ¥12.027bn, enhancing strategic and downside resilience. Total liabilities declined ¥493m YoY, or 32.9%, including a ¥483m reduction in current liabilities. Income taxes payable declined ¥423m YoY to ¥474m, accounting for much of the lower current-liability balance. Net PPE was broadly stable at ¥4.561bn, while buildings and structures increased ¥782m YoY to ¥2.892bn. Intangible assets declined ¥16m YoY, or 26.2%, to ¥45m; at just 0.2% of assets, this movement has no material bearing on capital quality. There is no balance-sheet goodwill concentration, and the low intangible asset base limits JGAAP goodwill-amortization or impairment-related earnings distortion.

Notable B/S Changes

Cash and deposits: +¥0.567bn (+5.0%) to ¥12.027bn - further strengthens an already cash-rich and low-risk liquidity profile. Buildings and structures: +¥0.782bn (+37.1%) to ¥2.892bn - indicates a material shift in fixed-asset composition and increases the importance of achieving adequate utilization and return on facilities. Retained earnings: +¥1.177bn (+6.4%) to ¥19.416bn - internally generated capital continues to fund the balance sheet and supports dividend capacity. Total liabilities: -¥0.493bn (-32.9%) to ¥1.006bn - reinforces the exceptionally conservative capital structure. Income taxes payable: -¥0.423bn (-47.2%) to ¥0.474bn - the principal contributor to the reduction in current liabilities. Intangible assets: -¥0.016bn (-26.2%) to ¥0.045bn - immaterial in absolute terms and only 0.2% of total assets, with limited effect on asset quality.

Cash Flow Quality

The reported earnings profile is operationally credible because ordinary income of ¥4.258bn closely matched operating income of ¥4.248bn and current-period profit included no extraordinary items. Working-capital efficiency is the material cash-conversion risk. The HIGH_INVENTORY_DAYS alert reflects annualized DIO of 217 days, far above the 90-day warning threshold. This is concerning because inventory held for more than seven months can increase the risk of slower sell-through, inventory write-downs, model obsolescence, and cash being tied up ahead of realized revenue. The alert is particularly relevant for a medical-device manufacturer, where product availability, regulatory requirements, and production lead times can justify some elevated stockholding, but 217 days remains materially above the stated manufacturing benchmark. Detailed inventory balances increased YoY in raw materials by 13.8% to ¥1.040bn, work in process by 26.9% to ¥618m, and finished goods by 16.8% to ¥453m, indicating that the concern is broad-based rather than isolated to finished goods. The LONG_CCC alert reflects an annualized cash conversion cycle of 237 days, well above the 120-day warning threshold. This is primarily inventory-driven: annualized receivable days are approximately 42 days, within the 45-day efficiency benchmark, whereas annualized payable days are approximately 21 days, below the 30-60 day benchmark. The short supplier-payment cycle amplifies the cash burden from inventory because the company pays suppliers well before inventory is converted into customer cash receipts. The impact on the investment case is reduced capital efficiency and a risk that strong accounting margins translate less efficiently into operating cash as the business scales. The substantial cash balance provides a strong buffer against this working-capital burden, but inventory turnover and final-quarter shipment conversion should be monitored closely.

Dividend Sustainability

The full-year dividend forecast is ¥41.00 per share against forecast EPS of ¥87.46, implying a dividend-only payout ratio of approximately 46.9%. This is below the 60% sustainability benchmark and appears conservatively supported by the company’s profitability and capital structure. The forecast dividend represents a total cash commitment of approximately ¥1.640bn based on 40.0 million issued shares. Forecast net income of ¥3.498bn covers that commitment by approximately 2.1x. Q3 cumulative net income of ¥2.817bn already exceeds the forecast annual dividend cash requirement by approximately 1.7x. Cash and deposits of ¥12.027bn provide substantial balance-sheet support for distributions. The absence of an interim Q2 dividend indicates that the planned ¥41.00 DPS is likely weighted toward the year-end payment. Working-capital efficiency remains relevant to distribution capacity because the 237-day annualized cash conversion cycle can absorb cash as inventories build. Even so, the low leverage profile, high margins, and retained earnings of ¥19.416bn support dividend sustainability under the stated forecast.

Risk Assessment

Business risks include Inventory and demand-conversion risk: annualized DIO of 217 days exceeds the 90-day warning level. The YoY rise in raw materials, WIP, and finished goods suggests greater production capital tied up ahead of sale; if medical-device demand, product mix, or shipment timing disappoints, inventory write-down and margin risks could emerge., Final-quarter margin risk: the full-year forecast implies approximately 42.2% Q4 operating margin, versus 53.5% in Q3 cumulative results. The implied step-down raises sensitivity to mix, pricing, manufacturing costs, and planned commercial spending., Medical-device industry risk: product quality, warranty, regulatory compliance, approvals, and potential recall exposure can create abrupt costs or disrupt sales. The current product-warranty provision is only ¥6m, or approximately 0.1% of Q3 revenue, but the sector remains exposed to low-frequency, high-impact quality events., Foreign-exchange exposure: FX gains were ¥48m, equal to 1.1% of operating income. The current contribution is not material, but foreign-currency movements may affect reported non-operating income and potentially procurement or export economics..

Financial risks include Long cash conversion cycle: the 237-day annualized CCC exceeds the 120-day warning threshold. The root cause is high inventory days combined with an approximately 21-day payable cycle; this can reduce cash efficiency despite high reported profitability., Concentration in cash and retained earnings: cash and deposits represent 58.9% of assets and retained earnings represent nearly all equity. This materially lowers solvency risk but increases the importance of disciplined capital allocation and productive deployment of excess liquidity., Tax-rate sensitivity: the 33.9% effective tax rate leaves a tax-burden factor of 0.661. With financing effects immaterial, changes in tax burden would flow relatively directly into net-income growth..

Key concerns include Highest priority: convert the elevated inventory position into revenue without discounting, write-downs, or additional gross-margin deterioration., High priority: reconcile Q4 execution with the forecasted margin step-down; operating-income progress is ahead of plan, but the annual plan still embeds a 7.1% YoY operating-profit decline., Moderate priority: monitor whether rapid profitability continues to be generated by core medical-device sales rather than favorable FX; current earnings are predominantly operating in nature., Low priority: solvency risk is limited by the 95.1% equity ratio, 0.05x D/E, and 4,248x interest coverage..

Investment Implications

Key takeaways include Revenue, operating income, and net income all increased YoY, with exceptionally high Q3 cumulative operating and net margins of 53.5% and 35.5%, respectively., Annualized ROE of 19.3% is high-quality in composition: it is driven by margin rather than leverage., Q3 results are tracking broadly in line with, or modestly ahead of, full-year guidance, with revenue at 74.8%, operating income at 79.0%, and net income at 80.5% of forecast., The principal counterweight to strong earnings is weak working-capital efficiency, highlighted by 217 annualized inventory days and a 237-day annualized CCC., The balance sheet has substantial resilience, with ¥12.027bn of cash, minimal liabilities, and a forecast dividend payout ratio of approximately 46.9%..

Metrics to watch include Q4 operating margin versus the approximately 42.2% margin implied by full-year guidance, Gross-margin trajectory after the 104bp YoY Q3 cumulative decline, Raw-material, WIP, and finished-goods inventory conversion and annualized DIO, Cash conversion cycle and supplier-payment terms, Achievement of ¥10.602bn revenue, ¥5.374bn operating income, and ¥3.498bn net income full-year forecasts, Capital allocation of the ¥12.027bn cash balance and delivery of the ¥41.00 per-share forecast dividend.

Regarding relative positioning, Relative to broad manufacturing benchmarks, the company combines unusually high operating profitability, low leverage, and abundant liquidity. Its weaker relative feature is working-capital intensity: inventory days and the cash conversion cycle are materially above standard manufacturing thresholds, making inventory discipline the key determinant of whether high accounting returns remain cash-efficient.